# Triple-negative breast cancer trials open today (registry snapshot and UK sites)

Source: https://onco.cc/terms/tnbc-trials-open-today/  
OnCo record `tnbc-trials-open-today` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Every phase 2 or 3 drug trial that was recruiting, about to open or still running for triple-negative breast cancer on ClinicalTrials.gov in September 2026, with the hospitals in the United Kingdom that take part named where the registry lists them.

## Summary

The ClinicalTrials.gov v2 API was searched on 24 September 2026 for interventional phase 2, 2/3 and 3 studies naming triple-negative breast cancer that were recruiting, not yet recruiting, enrolling by invitation or (for phase 3 and 2/3) active but closed to recruitment: 395 studies, of which 92 were already in the corpus and 18 are hand-written here. The 213 new registry-only records linked here carry the registry facts (title, sponsor, enrolment, dates, interventions, conditions, the triple-negative eligibility sentence and the countries) and no outcomes; trials with a HER2-positive or hormone-receptor-positive cohort alongside a triple-negative one are left out. Of the 213, 146 are phase 2, 32 phase 1/2, 31 phase 3 and 4 phase 2/3; 125 are recruiting, 75 not yet recruiting, 3 enrolling by invitation and 10 phase 3 or 2/3 trials active but closed. Most are run from China, the United States, France and Italy; the United Kingdom appears as a site in the hand-written UK trials (PARTNER at 30 hospitals, PHOENIX at 6, c-TRAK TN at 17, DIAMOND and BARBICAN at Barts, A-BRAVE at 8) and in the industry phase 3 trials ASCENT-03, ASCENT-04, ASCENT-05, TROPION-Breast02, 03, 04 and 05, CAPItello-290 and BEGONIA, whose UK sites are quoted on each record. The ISRCTN registry lists 41 hits for the same search, almost all dual-registered on ClinicalTrials.gov (DIAMOND is one), plus observational and imaging studies not carried here.

## Fields

- Kind: Term
- Last checked: 2026-09-24
- Also known as: TNBC trials recruiting; Open TNBC trials

## Sources

- ClinicalTrials.gov search: triple negative breast cancer, interventional, phase 2 and 3, recruiting: https://clinicaltrials.gov/search?cond=triple%20negative%20breast%20cancer&aggFilters=phase:2%203,status:rec%20not%20act,studyType:int
- ISRCTN registry search: triple negative breast: https://www.isrctn.com/search?q=triple+negative+breast

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- terms: [Combined positive score (CPS)](https://onco.cc/terms/cps/), [De-escalation, escalation and response-adapted therapy](https://onco.cc/terms/de-escalation/), [Pathologic complete response (pCR)](https://onco.cc/terms/pcr/), [Residual cancer burden (RCB)](https://onco.cc/terms/rcb/)
- trials: [A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer](https://onco.cc/trials/nct07078604/), [A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of S](https://onco.cc/trials/nct04333706/), [A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chem](https://onco.cc/trials/nct05862064/), [A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors](https://onco.cc/trials/nct06724263/), [A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer](https://onco.cc/trials/nct06878625/), [A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer](https://onco.cc/trials/nct06380816/), [A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.](https://onco.cc/trials/nct06889610/), [A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Tr](https://onco.cc/trials/nct06746870/), [A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) P](https://onco.cc/trials/nct07743190/), [A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer](https://onco.cc/trials/nct07441512/), [A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer](https://onco.cc/trials/nct06112379/), [A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC](https://onco.cc/trials/nct04501523/), [A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Ca](https://onco.cc/trials/nct07054242/), [A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced](https://onco.cc/trials/nct03168880/), [A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy fo](https://onco.cc/trials/nct07101614/), [A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance](https://onco.cc/trials/nct07321015/), [A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer](https://onco.cc/trials/nct07556848/), [A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inopera](https://onco.cc/trials/nct07729956/), [A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BC](https://onco.cc/trials/nct05999149/), [A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer](https://onco.cc/trials/nct07768436/), [A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC](https://onco.cc/trials/nct07376629/), [A Study of IOV-5001 in Adults With Advanced Solid Tumors](https://onco.cc/trials/nct07743723/), [A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct03742102/), [A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negat](https://onco.cc/trials/nct04683679/), [A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC](https://onco.cc/trials/nct07040644/), [A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer](https://onco.cc/trials/nct05570253/), [A Study of Tetrathiomolybdate (TM) Plus Capecitabine](https://onco.cc/trials/nct06134375/), [A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast](https://onco.cc/trials/nct04481763/), [A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negat](https://onco.cc/trials/nct06508216/), [A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC](https://onco.cc/trials/nct06632405/), [A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden](https://onco.cc/trials/nct07721259/), [A-BRAVE](https://onco.cc/trials/a-brave/), [Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy](https://onco.cc/trials/nct06268327/), [Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy](https://onco.cc/trials/nct04437160/), [Adjuvant Intensification for LAR](https://onco.cc/trials/nct07407517/), [Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer](https://onco.cc/trials/nct02455141/), [Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC](https://onco.cc/trials/nct05192798/), [All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi](https://onco.cc/trials/nct06636981/), [Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)](https://onco.cc/trials/nct05660083/), [Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers](https://onco.cc/trials/nct05296564/), [Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer](https://onco.cc/trials/nct05019690/), [Arsenous Acid for Refractory Triple-Negative Breast Cancer](https://onco.cc/trials/nct06678048/), [ASCENT-03](https://onco.cc/trials/ascent-03/), [ASCENT-04 / KEYNOTE-D19](https://onco.cc/trials/ascent-04/), [ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)](https://onco.cc/trials/ascent-05/), [ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation](https://onco.cc/trials/nct07015853/), [Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)](https://onco.cc/trials/nct04434040/), [Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients](https://onco.cc/trials/nct06690840/), [BARBICAN](https://onco.cc/trials/barbican/), [Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer](https://onco.cc/trials/nct06365788/), [Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial](https://onco.cc/trials/nct07610525/), [Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)](https://onco.cc/trials/nct07255612/), [BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC](https://onco.cc/trials/nct06793332/), [c-TRAK TN](https://onco.cc/trials/c-trak-tn/), [Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct06367088/), [Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer](https://onco.cc/trials/nct07107217/), [Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer](https://onco.cc/trials/nct07161791/), [Capecitabine in Low Risk Triple Negative Breast Cancer](https://onco.cc/trials/nct06787339/), [Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery](https://onco.cc/trials/nct05973864/), [Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC](https://onco.cc/trials/nct03997123/), [Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)](https://onco.cc/trials/nct04296175/), [Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy](https://onco.cc/trials/nct06992336/), [Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy](https://onco.cc/trials/nct05770531/), [Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer](https://onco.cc/trials/nct05475678/), [Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent](https://onco.cc/trials/nct07005583/), [Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Incl](https://onco.cc/trials/nct07762703/), [Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients](https://onco.cc/trials/nct07021261/), [Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study](https://onco.cc/trials/nct05067530/), [DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs](https://onco.cc/trials/nct06176261/), [DIAMOND](https://onco.cc/trials/diamond/), [Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer](https://onco.cc/trials/nct02488967/), [Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer](https://onco.cc/trials/nct07401537/), [Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer](https://onco.cc/trials/nct06229067/), [Efficacy of Interleukin-2 in Triple Negative Breast Cancer](https://onco.cc/trials/nct05821686/), [Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC](https://onco.cc/trials/nct07698106/), [Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptor](https://onco.cc/trials/nct06840821/), [Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies](https://onco.cc/trials/nct07340541/), [Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.](https://onco.cc/trials/nct05760378/), [First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.](https://onco.cc/trials/nct07299409/), [FMD and Neoadjuvant Chemo-immunotherapy in TNBC](https://onco.cc/trials/nct07378306/), [FMT in Triple Negative Breast Cancer Guided by ctDNA](https://onco.cc/trials/nct07292142/), [FUSCC Refractory TNBC Platform Study (FUTURE2.0)](https://onco.cc/trials/nct05749588/), [Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies](https://onco.cc/trials/nct07730125/), [Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer](https://onco.cc/trials/nct05528133/), [Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers](https://onco.cc/trials/nct05806385/), [HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.](https://onco.cc/trials/nct07528768/), [High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct06492759/), [HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer](https://onco.cc/trials/nct06849492/), [Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer](https://onco.cc/trials/nct06635980/), [Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients](https://onco.cc/trials/nct04159818/), [Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC](https://onco.cc/trials/nct07011823/), [Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients](https://onco.cc/trials/nct04677816/), [Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC](https://onco.cc/trials/nct06793553/), [Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK](https://onco.cc/trials/nct06358573/), [Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Origina](https://onco.cc/trials/nct03808337/), [JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC](https://onco.cc/trials/nct06731153/), [JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases](https://onco.cc/trials/nct06586866/), [JS207 Combination Therapy in Triple-negative Breast Cancer](https://onco.cc/trials/nct07045311/), [LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer](https://onco.cc/trials/nct06831955/), [LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer](https://onco.cc/trials/nct06387628/), [MicroRNA Profiles in Triple Negative Breast Cancer](https://onco.cc/trials/nct04771871/), [Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study](https://onco.cc/trials/nct06534762/), [Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer](https://onco.cc/trials/nct07371208/), [Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC](https://onco.cc/trials/nct06817525/), [Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer](https://onco.cc/trials/nct04159142/), [Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer](https://onco.cc/trials/nct04138719/), [Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer](https://onco.cc/trials/nct01057069/), [NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)](https://onco.cc/trials/nct06081244/), [Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC](https://onco.cc/trials/nct07743632/), [Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)](https://onco.cc/trials/nct07351487/), [Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)](https://onco.cc/trials/nct06682195/), [Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients](https://onco.cc/trials/nct06225284/), [Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC](https://onco.cc/trials/nct07016399/), [Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients](https://onco.cc/trials/nct06353997/), [Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer](https://onco.cc/trials/nct06407310/), [Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)](https://onco.cc/trials/nct07283692/), [Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.](https://onco.cc/trials/nct07394387/), [NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer](https://onco.cc/trials/nct07178730/), [Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemoth](https://onco.cc/trials/nct07372079/), [Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer](https://onco.cc/trials/nct06977542/), [Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer](https://onco.cc/trials/nct07457359/), [Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy](https://onco.cc/trials/nct06691594/), [Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer](https://onco.cc/trials/nct07188246/), [NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients](https://onco.cc/trials/nct06845319/), [Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients](https://onco.cc/trials/nct06795503/), [NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC](https://onco.cc/trials/nct04335669/), [NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial](https://onco.cc/trials/nct06342037/), [Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer](https://onco.cc/trials/nct05485766/), [Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer](https://onco.cc/trials/nct05522491/), [Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T](https://onco.cc/trials/nct06318897/), [OptimICE-pCR (A012103)](https://onco.cc/trials/optimice-pcr/), [Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)](https://onco.cc/trials/nct07581314/), [Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study](https://onco.cc/trials/nct07739485/), [Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TN](https://onco.cc/trials/nct06910072/), [PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC](https://onco.cc/trials/nct06533384/), [PARTNER](https://onco.cc/trials/partner/), [Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer](https://onco.cc/trials/nct06976944/), [Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy](https://onco.cc/trials/nct07486687/), [Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer](https://onco.cc/trials/nct05491083/), [Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC](https://onco.cc/trials/nct06078384/), [Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer](https://onco.cc/trials/nct07458204/), [Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct05269381/), [Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer](https://onco.cc/trials/nct06606730/), [PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC](https://onco.cc/trials/nct06245889/), [Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Secon](https://onco.cc/trials/nct07413601/), [Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery](https://onco.cc/trials/nct07723469/), [Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.](https://onco.cc/trials/nct02802423/), [Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy fo](https://onco.cc/trials/nct06771609/), [Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases](https://onco.cc/trials/nct05866432/), [Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Br](https://onco.cc/trials/nct07487519/), [Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer](https://onco.cc/trials/nct07017673/), [Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer](https://onco.cc/trials/nct07552181/), [Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer](https://onco.cc/trials/nct06889688/), [PHOENIX DDR/Anti-PD-L1](https://onco.cc/trials/phoenix/), [Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer](https://onco.cc/trials/nct06802757/), [Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer](https://onco.cc/trials/nct05806060/), [PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease](https://onco.cc/trials/nct07069595/), [Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer](https://onco.cc/trials/nct07276880/), [Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct06616987/), [Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC](https://onco.cc/trials/nct07103447/), [QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC](https://onco.cc/trials/nct06786026/), [QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer](https://onco.cc/trials/nct06404736/), [QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer](https://onco.cc/trials/nct07342283/), [QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.](https://onco.cc/trials/nct07509515/), [QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride](https://onco.cc/trials/nct07601178/), [Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer](https://onco.cc/trials/nct07419880/), [Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation](https://onco.cc/trials/nct05491226/), [Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel](https://onco.cc/trials/nct05582538/), [Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer](https://onco.cc/trials/nct07752550/), [Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases](https://onco.cc/trials/nct07623577/), [Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC](https://onco.cc/trials/nct07244874/), [Sac-TMT for Active TNBC Brain Metastases](https://onco.cc/trials/nct07458113/), [Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations](https://onco.cc/trials/nct07628504/), [Saci Nivo Rela for TNBC](https://onco.cc/trials/nct06963905/), [Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC](https://onco.cc/trials/nct04468061/), [Sacituzumab Govitecan and Q901 in Advanced TNBC](https://onco.cc/trials/nct07788222/), [Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases](https://onco.cc/trials/nct06238921/), [Sacituzumab Govitecan in Primary HER2-negative Breast Cancer](https://onco.cc/trials/nct04595565/), [Sacituzumab Govitecan In TNBC](https://onco.cc/trials/nct04230109/), [Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC](https://onco.cc/trials/nct07359404/), [Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC](https://onco.cc/trials/nct07007780/), [Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct07139470/), [Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct07153965/), [Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer](https://onco.cc/trials/nct05552001/), [SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC](https://onco.cc/trials/nct06627712/), [SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)](https://onco.cc/trials/nct06401005/), [SCARLET (SWOG S2212)](https://onco.cc/trials/scarlet-s2212/), [Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)](https://onco.cc/trials/nct05035745/), [Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer](https://onco.cc/trials/nct04768426/), [Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer](https://onco.cc/trials/nct04947189/), [SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer](https://onco.cc/trials/nct06819319/), [Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer](https://onco.cc/trials/nct04722978/), [Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC](https://onco.cc/trials/nct06165900/), [Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO](https://onco.cc/trials/nct05078047/), [Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)](https://onco.cc/trials/nct05909332/), [Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer](https://onco.cc/trials/nct06202313/), [Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)](https://onco.cc/trials/nct05447702/), [Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy](https://onco.cc/trials/nct06313463/), [Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)](https://onco.cc/trials/nct07011654/), [Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.](https://onco.cc/trials/nct07638852/), [SWOG S1418 / NRG BR006](https://onco.cc/trials/swog-s1418/), [TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature](https://onco.cc/trials/nct02641847/), [Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC](https://onco.cc/trials/nct07786428/), [Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer](https://onco.cc/trials/nct06434064/), [Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)](https://onco.cc/trials/nct05128734/), [Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct03606967/), [Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Lo](https://onco.cc/trials/nct07151586/), [The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast](https://onco.cc/trials/nct06851299/), [The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breas](https://onco.cc/trials/nct06140576/), [The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospec](https://onco.cc/trials/nct06125080/), [The Optimal Radioimmunotherapy Combinations for Advanced TNBC](https://onco.cc/trials/nct06735131/), [The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer](https://onco.cc/trials/nct05550415/), [The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC](https://onco.cc/trials/nct05862610/), [TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer](https://onco.cc/trials/nct06532812/), [TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC](https://onco.cc/trials/nct07074106/), [Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Mu](https://onco.cc/trials/nct06538896/), [Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Dis](https://onco.cc/trials/nct07681297/), [to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versu](https://onco.cc/trials/nct04301739/), [Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers](https://onco.cc/trials/nct05846789/), [Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer](https://onco.cc/trials/nct07256964/), [Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS](https://onco.cc/trials/nct05451784/), [Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT](https://onco.cc/trials/nct04137653/), [TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer](https://onco.cc/trials/nct07271992/), [Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab](https://onco.cc/trials/nct06371807/), [Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies](https://onco.cc/trials/nct07064018/), [Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer](https://onco.cc/trials/nct06291064/), [Triple Negative Breast Cancer and Celecoxib. Pilot Study](https://onco.cc/trials/nct07104266/), [TROPION-Breast02](https://onco.cc/trials/tropion-breast02/), [TROPION-Breast03](https://onco.cc/trials/tropion-breast03/), [TROPION-Breast05](https://onco.cc/trials/tropion-breast05/), [Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy](https://onco.cc/trials/nct06385990/)

---
JSON: https://onco.cc/api/v1/entities/tnbc-trials-open-today.json